Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

necitumumab

Bayer symbol

Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

The results from the study will support regulatory applications for wider use of the drug

- PMLiVE

Phesi publishes new analysis revealing top five most studied diseases globally

The analysis also showed that 32% of phase 2 trials were terminated in the first half of 2024

- PMLiVE

Ipsen gains global rights to Foreseen’s ADC candidate in deal worth up to $1.03bn

FS001 is currently completing the final stages of preclinical development

- PMLiVE

WHO publishes guidance for HPV vaccine developers to help tackle cervical cancer

In more than nine out of ten cases, the HPV virus leads to cervical cancer, the fourth most common cancer in women globally

- PMLiVE

Hologic survey reveals major screening action gap in millions of US women

An estimated 72 million women in the US have skipped or delayed recommended preventative screening

- PMLiVE

Study reveals GLP-1s could reduce risk of cancer in patients with type 2 diabetes

GLP-1 treatment reduced the risk of gallbladder cancer by 65% and meningioma by 63%

- PMLiVE

Eli Lilly to expand chronic disease pipeline with $3.2bn Morphic acquisition

The deal includes a candidate in mid-stage clinical development for inflammatory bowel disease

- PMLiVE

Study identifies thousands of high-risk cancer gene variants and potential therapeutic target

Patients with inherited variants of the BAP1 gene have a 50% increased risk of developing certain cancers

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla granted FDA approval for early symptomatic disease

The amyloid plaque-targeting therapy could result in lower treatment costs and fewer infusions

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Eli Lilly partners with OpenAI to discover antimicrobials for drug-resistant pathogens

Antimicrobial resistance has been declared by WHO as one of the top ten global public health threats

- PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links